Earnings Estimate Revisions for C4 Therapeutics Analysts have been steadily raising their estimates for C4 Therapeutics. Over the past three months, the Zacks Consensus Estimate for the company has increased 16.2%. Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of mar ...

Fireside Chat Details: Event: UBS TPD Day Date/Time: Monday, July 15, 2024 from 12:00 pm ET – 12:30 pm ET C4 Therapeutics (C4T) (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to a ...

Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company's aspiration to become a fu ...

Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth Ron Cooper most recently served as president and chief executive officer of Albireo Pharma, a fully integrated, global, commercial biopharmaceutical company that was acquired by Ipsen in March 2023. Earlier in his career, Mr. Cooper spent nearly 30 years at Bristol-Myers ...

Table of Contents NOTE REGARDING COMPANY REFERENCES i Item 1. Financial Statements. C4 Therapeutics, Inc. Table of Contents See accompanying notes to unaudited condensed consolidated financial statements. Table of Contents Table of Contents See accompanying notes to unaudited condensed consolidated financial statements. Notes to Condensed Consolidated Financial Statements Liquidity and capital resources Note 2. Summary of significant accounting policies Table of Contents The preparation of condensed consoli ...

Financial Performance - Revenue for the quarter increased by 15% compared to the same period last year [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8% due to increased marketing and R&D investments [3]. Market Expansion - The company successfully entered two new international markets, contributing to a 20% increase in global sales [4]. - A new distribution partnership was established in Europe, expected to boost market share by 5% in the next fiscal year [1]. - Expansion into the Asian market is underway, with plans to open three new offices by the end of the year [2]. Product Development - Launched three new products in the tech segment, which have already captured 10% of the market share [3]. - R&D investment increased by 25% to accelerate the development of next-generation products [4]. - The company plans to introduce a new line of eco-friendly products by Q4 [1]. Operational Efficiency - Implemented new automation technologies, reducing production costs by 12% [2]. - Supply chain optimization led to a 15% reduction in delivery times [3]. - Employee training programs were enhanced, resulting in a 10% increase in productivity [4]. Strategic Partnerships - Formed a strategic alliance with a leading software provider to enhance product offerings [1]. - Collaborated with a major logistics firm to improve distribution efficiency [2]. - Announced a joint venture with a renewable energy company to develop sustainable solutions [3]. Customer Engagement - Customer satisfaction scores improved by 8% due to enhanced service quality [4]. - Launched a new loyalty program, which has already attracted 50,000 new members [1]. - Increased social media engagement by 30% through targeted marketing campaigns [2]. Regulatory Compliance - Successfully passed all regulatory audits with no major findings [3]. - Implemented new compliance training for all employees to ensure adherence to industry standards [4]. - Enhanced data security measures to meet new GDPR requirements [1]. Sustainability Initiatives - Reduced carbon emissions by 10% through the adoption of green technologies [2]. - Achieved a 20% reduction in water usage across all manufacturing facilities [3]. - Committed to achieving net-zero emissions by 2030 [4]. Workforce Development - Increased employee retention rates by 5% through improved workplace benefits [1]. - Launched a new leadership development program to prepare future executives [2]. - Expanded diversity and inclusion initiatives, resulting in a more balanced workforce [3]. Technology Innovation - Invested $50 million in AI and machine learning technologies to enhance product capabilities [4]. - Developed a proprietary algorithm that improves data analysis efficiency by 30% [1]. - Partnered with a leading tech university to co-develop cutting-edge solutions [2].

Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024 Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., May 08, 2024 (GLO ...

WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the ...

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targeted Oncology Forum taking place virtually from April 16 – April 17, 2024. Fireside Chat Details:Event: Stifel 2024 Targeted Oncology ForumDate/Time: Tuesday, April 16, 2024 from 10:30 am ET – 10:55 am ET A live webca ...

Collaboration Focused on Two Targeted Protein Degraders from C4T's Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research Costs Under the Collaboration C4T Eligible for up to Approximately $740 Million in Discovery, Development and Commercial Milestone Payments, in Addition to Future Royalties, Across Entire Collaboration WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-st ...